THE DEAL, AT A GLANCE
From the announcementMerus
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedMerus raised $125M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersMerus is positioned around Zenocutuzumab for rare NRG1 fusion cancer, an indication described as having no approved therapy, supported by a reported 33% ORR and $125M in…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Merus · Financing Record
Explore source-linked visual explanations for Merus. Unsupported claims are withheld while source review continues.
Record 1116 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →